When a knee injury leaves too much damage for standard repairs

A significant knee injury — a fracture through the joint surface, a high-energy impact, or a severe osteochondritis dissecans episode — can strip away not just the cartilage layer but the layer of bone directly beneath it. That combined loss is the clinical problem that most cartilage repair techniques were not designed to solve. Microfracture stimulates a fibrocartilage patch rather than true cartilage, and works best for smaller defects under about 2 cm². Cell-based treatments such as MACI restore the surface but cannot rebuild the bone scaffold below. When both layers are gone across a substantial area, neither approach addresses the full extent of what has been lost.

Fresh osteochondral allograft (OCA) transplantation is the option surgeons turn to in this situation. A carefully matched section of donor bone and intact overlying hyaline cartilage is taken from a tissue bank and shaped to fill the defect precisely — replacing the same structures, layer for layer, in a single operation. The cartilage transferred is mature and zonal in structure, the same tissue type as healthy articular cartilage, rather than the lower-quality fibrocartilage that forms after marrow-stimulation procedures.

The procedure is most commonly used for defects larger than 2–4 cm², a threshold where other techniques are generally considered inadequate. In a series of 156 knees treated by Tirico and colleagues, the mean allograft area was 6.4 cm² — reflecting the scale of the injuries this approach is designed to address. Giorgini et al. (Injury, 2013) specifically confirmed OCA as a suitable option for wide cartilage defects in the knee where nothing smaller in scope would reliably suffice.

Why post-traumatic defects are harder to repair than other cartilage injuries

Cartilage has no blood supply of its own. Unlike bone or muscle, which draw on a vascular network to begin healing after injury, articular cartilage must rely on nutrients diffusing slowly from the joint fluid around it. That arrangement works well enough when the surface sustains only minor wear, but it means the tissue has almost no capacity to repair itself once a significant gap appears.

A traumatic injury — a high-energy impact, a fracture through the joint surface — does not stop at the cartilage layer. The force typically drives through into the subchondral bone: the dense, load-bearing bone that sits directly beneath the cartilage and acts as its structural foundation. Think of it as tiles on a concrete base. Replacing the tiles is straightforward only if the concrete underneath is still sound. When the base itself has been damaged or lost, new tiles have nothing firm to bond to and will not last under the repetitive loading of everyday movement.

This is the defining challenge of post-traumatic osteochondral lesions. Techniques that work by stimulating the bone marrow — or that restore only the surface cartilage layer — address the tiles but leave the damaged base untouched. Without a stable subchondral scaffold, any cartilage that forms or is placed on top lacks mechanical support and is liable to break down under load far sooner than healthy cartilage would. Rebuilding both layers together is not a refinement; it is a structural necessity.

Why 'fresh' allograft is biologically different from other graft options

The word 'fresh' in this context is a precise clinical term, not a description of how recently the graft was packaged. It distinguishes allografts that contain living chondrocytes from those that have been frozen or freeze-dried for storage. Cryopreservation and freeze-drying are practical for tissue banking but they destroy the cells within the cartilage; what remains is structural scaffolding without biological activity. Transplanting that material moves the architecture of cartilage without any of the living tissue that sustains it.

In a fresh graft, donor chondrocytes survive within the intact extracellular matrix — the collagen-proteoglycan framework they produced and continue to maintain. Retrieval studies of successfully integrated grafts have confirmed viable chondrocytes and relatively preserved matrix years after transplantation. Those cells, once the graft is fixed in place and the joint begins to load it, continue functioning as if they were the recipient's own — producing and remodelling the matrix that gives cartilage its mechanical properties.

There is a practical constraint attached to this biological advantage. Chondrocyte viability declines noticeably from around Day 14 after procurement and falls below the accepted clinical threshold of approximately 70% viable cells by Day 28. That 28-day window means tissue banking, size-matching, and surgical scheduling must all align within a narrow timeframe — which can affect how quickly a graft becomes available.

A common concern with any allograft is immune rejection. Two retrieval studies of failed fresh osteochondral allografts found little or no histological evidence of immune-mediated damage and no signs of frank rejection. Recipients do not require immunosuppression, which supports OCA's routine use without the systemic risks that accompany transplantation in other contexts.

How OCA compares to microfracture, OATS, and MACI for large defects

Each of the main alternatives to OCA has a defined ceiling — a point at which defect size, tissue biology, or structural anatomy makes the technique inadequate. Understanding where those ceilings sit explains why large post-traumatic lesions occupy a category of their own.

Microfracture remains historically important as the most widely used marrow-stimulation procedure, but its limitations are now well established. Drilling through the subchondral plate allows bone-marrow cells to migrate into the defect and form repair tissue, but that tissue is fibrocartilage — collagen-type-I dominant, mechanically inferior to the native hyaline surface, and prone to degrading under cyclic load within two to three years. There is an additional structural cost: the procedure itself can disrupt the subchondral bone plate and make subsequent repair options more difficult. For defects below 2 cm², it may still have a role; for larger lesions, the evidence does not support it as a modern first-line choice.

OATS and mosaicplasty transfer osteochondral plugs from a non-load-bearing donor site — genuine hyaline cartilage on intact bone — and therefore offer better tissue quality than microfracture. The constraint is area: single-plug OATS covers approximately 1–2 cm², and mosaic configurations extend this to around 4 cm². Beyond that ceiling, harvesting enough plugs incurs meaningful donor-site morbidity without reliably filling the defect. In the 6 cm² range typical of post-traumatic lesions (Tirico et al. reported a mean allograft area of 6.4 cm²), mosaicplasty simply cannot provide sufficient coverage.

MACI — matrix-induced autologous chondrocyte implantation — addresses larger surface areas, with an indication range of roughly 2–10 cm², and the SUMMIT trial demonstrated superior KOOS pain and function scores versus microfracture for defects of 3 cm² or more at both 2 and 5 years. However, MACI repairs the cartilage layer only. It cannot reconstitute subchondral bone loss — the defining structural feature of post-traumatic osteochondral injury described in the previous section. It also requires two surgical stages: a biopsy to harvest chondrocytes, a period of cell culture, and then re-implantation. First-generation ACI shares both limitations and carries a higher failure rate when prior marrow-stimulation procedures have already been performed.

OCA is the only single-stage technique that replaces cartilage and its subchondral bone scaffold simultaneously, using tissue that already contains organised, zonal hyaline cartilage maintained by viable donor chondrocytes. For post-traumatic defects above approximately 4 cm² — where the bone beneath the cartilage is structurally compromised — that combination is not a technical preference but a biological requirement. Direct head-to-head randomised trials comparing OCA with MACI for large defects remain limited, so comparative conclusions rest largely on single-centre series and mechanistic reasoning rather than RCT evidence.

Long-term survivorship: what the evidence shows over decades

The survivorship data for fresh OCA span longer follow-up periods than virtually any competing biological repair technique, which carries particular weight for younger patients weighing cartilage preservation against eventual joint replacement.

At defined hard endpoints — conversion to total knee arthroplasty, revision of the allograft, or a Hospital for Special Surgery score falling below 70 — published series report survivorship of approximately 82.6% at five years and 69.6% at ten years. A separate long-term analysis found 68% of grafts (44 of 65) still in situ and functioning at a mean of 12.9 years, with Kaplan-Meier survivorship of 95% at that interval. Gross et al. (Clin Orthop Relat Res, 2008) established the foundational long-term data specifically for post-traumatic knee defects, and remains the landmark reference for this indication. The most striking published follow-up comes from Raz et al. (J Bone Joint Surg Am, 2014), who reported outcomes of distal femoral fresh OCA at a mean of 22 years — longevity that no other biological cartilage repair technique has matched at comparable scale.

There is an honest caveat: defects larger than approximately 8 cm² show lower survivorship than smaller grafts in published series, suggesting a practical upper boundary to technique efficacy. For very extensive lesions the outcomes become less predictable, and realistic patient counselling should reflect that.

When a primary graft does fail, the pathway does not move directly to replacement. Horton et al. (Am J Sports Med, 2013) confirmed that revision OCA transplantation is viable, preserving total knee arthroplasty as a downstream salvage option rather than the immediate next step — an important reassurance when discussing long-term planning with patients in their thirties or forties.

The evidence base is predominantly retrospective single-centre series rather than randomised trials. The duration and breadth of follow-up across independent cohorts does, however, provide a degree of clinical confidence that short-term trial data alone cannot offer.

Who is suitable, what to expect, and how to access assessment

Deciding whether OCA is the right pathway begins with a structured clinical assessment. Several factors consistently define the eligible group — and being honest about the boundaries is as useful as describing the ideal candidate.

Defect characteristics. The technique is designed for full-thickness osteochondral lesions typically exceeding 2–4 cm², where cartilage and the subchondral bone beneath it have both been lost. Patients with smaller isolated cartilage defects, or with surface damage limited to one layer, are generally better served by one of the single-stage or cell-based options described earlier.

Joint alignment. Significant varus or valgus malalignment concentrates load directly onto the repair site and can accelerate graft failure. Where malalignment is present, a corrective osteotomy — HTO for varus, DFO for valgus — may be considered alongside OCA to protect the graft long-term. This is evaluated as part of the pre-treatment assessment, not a separate decision the patient needs to make independently.

Extent of arthritis. OCA addresses focal osteochondral loss in an otherwise reasonably preserved joint. Diffuse or advanced osteoarthritis throughout the knee shifts the balance towards joint replacement rather than cartilage preservation, and a careful assessment is needed to distinguish the two.

Graft scheduling. Because of the viability window described earlier, implantation timing is partly governed by tissue bank logistics. Patients should expect some flexibility in scheduling once a size-matched graft becomes available.

A weight-bearing knee MRI, reviewed with cartilage-sensitive sequences to characterise lesion depth and extent, is the starting point for any suitability decision. Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral — assessments can be arranged directly at lincolnshireknee.co.uk.